EP1102788A4 - PREVENTION AND TREATMENT OF VIRAL DISEASES - Google Patents

PREVENTION AND TREATMENT OF VIRAL DISEASES

Info

Publication number: EP1102788A4
Authority: EP; European Patent Office
Prior art keywords: prevention; treatment; viral diseases; viral; diseases
Prior art date: 1998-08-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP99945011A

Other languages

German (de)

French (fr)

Other versions

EP1102788A2 (en

Inventor

Jack H Nunberg

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Montana

Original Assignee

University of Montana

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-03

Filing date

1999-08-03

Publication date

2002-08-28

1999-08-03 Application filed by University of Montana filed Critical University of Montana

2001-05-30 Publication of EP1102788A2 publication Critical patent/EP1102788A2/en

2002-08-28 Publication of EP1102788A4 publication Critical patent/EP1102788A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP99945011A 1998-08-03 1999-08-03 PREVENTION AND TREATMENT OF VIRAL DISEASES Withdrawn EP1102788A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US9510598P	1998-08-03	1998-08-03
US95105P		1998-08-03
US14180699P	1999-06-29	1999-06-29
US141806P		1999-06-29
PCT/US1999/017487 WO2000008043A2 (en)	1998-08-03	1999-08-03	Prevention and treatment of viral disease

Publications (2)

Publication Number	Publication Date
EP1102788A2 EP1102788A2 (en)	2001-05-30
EP1102788A4 true EP1102788A4 (en)	2002-08-28

Family

ID=26789760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP99945011A Withdrawn EP1102788A4 (en)	1998-08-03	1999-08-03	PREVENTION AND TREATMENT OF VIRAL DISEASES

Country Status (9)

Country	Link
EP (1)	EP1102788A4 (en)
JP (1)	JP2002522448A (en)
KR (1)	KR20010085326A (en)
CN (1)	CN1321165A (en)
AU (1)	AU5771599A (en)
BR (1)	BR9912732A (en)
CA (1)	CA2338983A1 (en)
IL (1)	IL141211A0 (en)
WO (1)	WO2000008043A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6025154A (en)	1995-06-06	2000-02-15	Human Genome Sciences, Inc.	Polynucleotides encoding human G-protein chemokine receptor HDGNR10
JP2002533124A (en)	1998-12-31	2002-10-08	カイロンコーポレイション	Improved expression of HIV polypeptide and generation of virus-like particles
EP1141314A2 (en)	1998-12-31	2001-10-10	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
FR2789590B1 (en) *	1999-02-15	2003-01-17	Inst Rech Developpement Ird	IMMUNOGENIC COMPOSITIONS FOR USE AS VACCINES
EP1130089A1 (en) *	2000-02-17	2001-09-05	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Composition comprising membrane virus subviral target and fusion particles and vaccine comprising said composition
US7033593B2 (en)	2000-09-22	2006-04-25	Duke University	Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
WO2002024149A2 (en) *	2000-09-22	2002-03-28	Duke University	Immunogen comprising ligand bound hiv envelpe protein
EP1368478B1 (en) *	2001-01-05	2006-04-26	Sanofi Pasteur	Polypeptide inducing hiv-neutralising antibodies
FR2819256B1 (en) *	2001-01-05	2004-04-30	Aventis Pasteur	POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES
US7175988B2 (en)	2001-02-09	2007-02-13	Human Genome Sciences, Inc.	Human G-protein Chemokine Receptor (CCR5) HDGNR10
EP2412242A3 (en)	2001-07-05	2012-06-13	Novartis Vaccines and Diagnostics, Inc.	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7393934B2 (en)	2001-12-21	2008-07-01	Human Genome Sciences, Inc.	Human G-protein chemokine receptor (CCR5) HDGNR10
WO2005105841A2 (en)	2004-03-12	2005-11-10	Human Genome Sciences, Inc.	Human g-protein chemokine receptor (ccr5) hdgnr10
GB201412494D0 (en)	2014-07-14	2014-08-27	Ospedale San Raffaele And Fond Telethon	Vector production

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993000103A1 (en) *	1991-06-21	1993-01-07	The Wistar Institute Of Anatomy And Biology	Chimeric envelope proteins for viral targeting
AU2512792A (en) *	1991-08-30	1993-04-05	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Defective interfering hiv particles with chimeric cd4-env

1999
- 1999-08-03 WO PCT/US1999/017487 patent/WO2000008043A2/en not_active Application Discontinuation
- 1999-08-03 KR KR1020017001483A patent/KR20010085326A/en not_active Application Discontinuation
- 1999-08-03 IL IL14121199A patent/IL141211A0/en unknown
- 1999-08-03 BR BR9912732-6A patent/BR9912732A/en not_active IP Right Cessation
- 1999-08-03 JP JP2000563676A patent/JP2002522448A/en active Pending
- 1999-08-03 EP EP99945011A patent/EP1102788A4/en not_active Withdrawn
- 1999-08-03 CA CA002338983A patent/CA2338983A1/en not_active Abandoned
- 1999-08-03 CN CN99811641A patent/CN1321165A/en active Pending
- 1999-08-03 AU AU57715/99A patent/AU5771599A/en not_active Abandoned

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LACASSE ET AL.: "Fusion-competent vaccines: Broad neutralization of primary isolates of HIV", SCIENCE, vol. 283, 15 January 1999 (1999-01-15), pages 357 - 362, XP002120812 *
NUNBERG, J.: "Retraction", SCIENCE, vol. 296, 10 May 2002 (2002-05-10), pages 1025 *
THALI ET AL.: "Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding", J. VIROLOGY, vol. 67, no. 7, July 1993 (1993-07-01), pages 3978 - 3988, XP000579277 *
WHITE-SCHARF: "Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization", VIROLOGY, vol. 192, 1993, pages 197 - 206, XP002203539 *
WYATT & SODROSKI: "The HIV-1 envelope glyycoproteins: fusogens, antigens and immunogens", SCIENCE, vol. 280, 19 June 1998 (1998-06-19), pages 1884 - 1888, XP002203540 *

Also Published As

Publication number	Publication date
EP1102788A2 (en)	2001-05-30
IL141211A0 (en)	2002-02-10
JP2002522448A (en)	2002-07-23
BR9912732A (en)	2001-11-27
CN1321165A (en)	2001-11-07
WO2000008043A2 (en)	2000-02-17
CA2338983A1 (en)	2000-02-17
WO2000008043A3 (en)	2000-05-11
KR20010085326A (en)	2001-09-07
WO2000008043A9 (en)	2001-12-13
AU5771599A (en)	2000-02-28

Publication	Publication Date	Title
ATE434444T1 (en)	2009-07-15	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
ATE399016T1 (en)	2008-07-15	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
DE60023128D1 (en)	2006-02-23	PYRAZOLECARBOXAMIDE FOR THE TREATMENT OF FATIBILITY AND OTHER DISEASES
ATE358418T1 (en)	2007-04-15	ANTIMICROBIAL PREVENTION AND TREATMENT OF AIDS AND OTHER INFECTIOUS DISEASES
DE69925306D1 (en)	2005-06-16	TREATMENT OF HYDROCARBONGAS
DE69926385D1 (en)	2005-09-01	TREATMENT OF TISSUE
DE69737793D1 (en)	2007-07-19	BENZIMIDAZOLE-2-CARBAMATE FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER
ATE417602T1 (en)	2009-01-15	AGENTS FOR THE TREATMENT OF DISEASES OF THE ESOPHAUS
ATE349216T1 (en)	2007-01-15	TREATMENT OF INTESTINAL CONSTITUTION
DE69830728D1 (en)	2005-08-04	MEDICAMENT FOR THE TREATMENT OF COMMON WATER AND HARN INCONTINENCE
DE69903543D1 (en)	2002-11-21	FORMULATIONS FOR THE TREATMENT OF REFLUX GENTLE EYES
DE69806801D1 (en)	2002-08-29	GALENIC PREPARATION FOR THE PREVENTION AND TREATMENT OF HEPATOCARCINOMA
DE69729817D1 (en)	2004-08-19	Treatment of aldehyde-fixed tissues
EP1102788A4 (en)	2002-08-28	PREVENTION AND TREATMENT OF VIRAL DISEASES
DE69836209D1 (en)	2006-11-30	PREVENTION AND TREATMENT OF HEPATOCELLULAR CANCER
EP1416957A4 (en)	2006-08-02	TREATMENT OF IMMUNE DISEASES AND B-CELL DISEASES
EP1117431A4 (en)	2005-03-02	TREATMENT OF ACIDOSE
DE69841550D1 (en)	2010-04-22	TREATMENT OF FIBROMYALGIA AND RELATED DISEASES
DE69620691D1 (en)	2002-05-23	Therapeutic agent for the treatment of hypercholesterolemia
DE69825319D1 (en)	2004-09-02	PREPARATION FOR THE PREVENTION AND TREATMENT OF INFLAMMATION
EP1239851A4 (en)	2005-09-14	TREATMENT OF HYPERPROLIFERATIVE DISEASES
ATE314064T1 (en)	2006-01-15	L-ACETYLCARNITINE AND L-PROPIONYLCARNITINE COMPOSITION FOR THE PREVENTION AND TREATMENT OF KIDNEY DISORDERS AND KIDNEY DISEASE
ATE443060T1 (en)	2009-10-15	BENZOAQUINOLINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA AND MIOPSIGHTEDNESS
DE69522685D1 (en)	2001-10-18	TREATMENT OF BLOOD PLASMA
ATE218866T1 (en)	2002-06-15	COMBINATION THERAPY FOR THE TREATMENT OF AIDS

Legal Events

Date	Code	Title	Description
2001-04-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-05-30	17P	Request for examination filed	Effective date: 20010302
2001-05-30	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-05-30	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2002-08-14	RIC1	Information provided on ipc code assigned before grant	Free format text: 7C 07H 21/04 A, 7A 61K 48/00 B, 7A 61K 39/395 B, 7C 12N 1/20 B, 7A 61K 39/21 B, 7C 07K 14/16 B, 7C 12N 15/62 B
2002-08-28	A4	Supplementary search report drawn up and despatched	Effective date: 20020711
2002-08-28	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-07-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2003-09-03	18D	Application deemed to be withdrawn	Effective date: 20030302